BioSpace News Archive

Concentric Analgesics, Inc. today announced the podium presentation of clinical data for vocacapsaicin, its first-in-class non-opioid lead product candidate for the management of postsurgical pain, at the 46th Annual Regional Anesthesiology and Acute Pain Medicine (ASRA) Meeting on May 13, 2021 in Orlando, Florida.

Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting - Data demonstrates Seres’ leadership in microbiome sciences and therapeutics across multiple diseases -

Updated long-term efficacy and safety data of Vitrakvi® (larotrectinib) for patients with TRK fusion cancer from an integrated dataset, sub-analyses for TRK fusion cancer patients with primary central nervous system (CNS) tumors and lung cancer, respectively, as well as updated results from an intra-patient comparison to be featured

Gregory T. Lucier named Board Chairperson, succeeding Michael Marks John Chiminski joins Board as an Independent Director EMERYVILLE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced that Gregory T. Lucier has been named Chairperson of the Board of Directors, effective May 14, 2021. He will succeed Michael Marks, who is retiring from the Board. Concurrent with this appointment, John Chiminski, chief executive

Financing will advance Aetion’s technology, accelerate global growth, and drive expansion in new verticals, further cementing Aetion’s leadership position in real-world evidence

STALICLA SA, a Swiss clinical stage biopharmaceutical company leading omics-based precision medicine drug development for patients with neurodevelopmental disorders, announced the appointment of Baltazar Gomez-Mancilla, MD, PhD, to the position of Chief Medical Officer.

Immatics’ second TCR Bispecifics program IMA402 demonstratestumor cell killing in vitro and complete regressions of established tumors in anin vivo tumor model

OVAL Phase 3 registration-enabling study investigating VB-111 in patients with platinum-resistant ovarian cancer remains on track in spite of COVID-19, with over 260 patients enrolled; next DSMC review expected 3Q21

Xtant Medical Holdings, Inc., a global medical technology company focused on surgical solutions for the treatment of spinal disorders, reported financial and operating results for the first quarter ended March 31, 2021.

Phase 3 ROMAN trial in severe oral mucositis expected to complete enrollment in 1H21; topline data expected in 2H21